About us
Our History
Phio’s founders opened up a whole new field of immunology, revolutionizing the way scientists think about precision medicine.
Today we continue that vision in the development of therapeutics using INTASYL, our proprietary siRNA technology, which is derived from RNAi. INTASYL is designed to make immune cells more effective in killing tumor cells in treating unmet medical needs.
Our Focus
Phio's focus is centered on the application of self-delivering RNAi therapies in the field of immuno-oncology designed to silence specific genes that are implicated in the proliferation of solid cancer tumors.
In addition to self-directed research, Phio also seeks collaborative partnerships in product development with companies that have an interest in immuno-oncology, including those companies with a dermatologic focus.
In addition to self-directed research, Phio also seeks collaborative partnerships in product development with companies that have an interest in immuno-oncology, including those companies with a dermatologic focus.
Leadership
Our Vision
To advance new pathways toward a cancer free future.
Our Mission
To develop our patented siRNA therapies which enable our body’s own defenses to overcome cancer.
Science & Pipeline
Investors
Contact us
Follow us on LinkedIn
